ABSTRACT Objective This study compared weight‐loss outcomes in patients prescribed tirzepatide by weight‐loss status and assessed results among patients transitioning from semaglutide. Methods This retrospective cohort study analyzed 6‐month weight‐loss outcomes in adults treated with tirzepatide between May 2022 and January 2023. Patients were classified as weight‐reduced if they had lost ≥ 10% total body weight (TBW) before starting tirzepatide. Among those who switched from therapeutic semaglutide (≥ 1.7 mg weekly for ≥ 1 month), reasons for switching were categorized as non‐response (< 5% weight loss after ≥ 3 months), plateau (≥ 5% loss followed by weight stabilization), or other. Results Of 941 charts, 293 (31.1%) met inclusion criteria (65% female; mean age 52 years; mean BMI 36.15 kg/m 2 ). Weight‐reduced patients ( n = 133) lost 7.2% TBW versus 10.3% in non‐weight‐reduced patients ( n = 160; p < 0.001). When analyses were stratified by type 2 diabetes (T2D) status, this difference remained significant among patients without T2D. Sixty‐one patients switched from semaglutide due to non‐response or plateau and lost 5.3% TBW. Those switching at a plateau ( n = 28) lost 8.1% versus 2.9% for non‐responders ( n = 33; p < 0.001). Conclusions Tirzepatide produced meaningful weight loss across groups but outcomes varied based on weight‐reduction status, T2D status, and prior response to semaglutide.
Barenbaum et al. (Sat,) studied this question.